Related Experiment Video

Updated: May 26, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

[Pharmacotherapy of chronic heart failure after the first decade of 21st century]

J Spinar1, J Vítovec, L Spinarová

  • 1Interní kardiologická klinika Lékarsé fakulty MU a FN Brno. jspinar@fnbrno.cz

Vnitrni Lekarstvi
|December 15, 2011
PubMed

Insights

Pharmacological treatments for chronic heart failure have advanced significantly. Key therapies include ACE inhibitors, ARBs, and beta-blockers, with new drug classes emerging.

Area of Science:

  • Cardiology
  • Pharmacology

Context:

  • Chronic heart failure (CHF) is a major 21st-century health concern, affecting approximately 200,000 individuals in the Czech Republic.
  • Significant advancements in both pharmacological and non-pharmacological CHF treatments have occurred over the past decade.
  • Continuous new research emerges annually, refining our understanding and management of heart failure.

Purpose:

  • To provide a comprehensive overview of the primary principles guiding the pharmacological management of chronic heart failure.
  • To discuss the established and evolving therapeutic strategies for CHF.

Summary:

  • Standard pharmacological interventions for CHF include Angiotensin-Converting Enzyme (ACE) inhibitors, Angiotensin II Receptor Antagonists (ARBs), and beta-blockers.
  • The roles of digoxin, diuretics, and lipid-lowering drugs are subjects of ongoing discussion.
  • Recent years (2009-2011) introduced novel drug classes, such as If channel blockers, factor Xa inhibitors, and thrombin inhibitors, expanding treatment options.

Impact:

  • This overview aids clinicians in navigating the complex landscape of heart failure pharmacotherapy.
  • Understanding these principles is crucial for improving patient outcomes in chronic heart failure.
  • The emergence of new drug classes signifies a paradigm shift in managing this prevalent condition.

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...